SENTARA HEALTH PLANS
PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Orencia® SQ (abatacept) **(Pharmacy)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

NOTE: The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

❑ Will the member be discontinuing a previously prescribed biologic if approved for requested medication?

❑ Yes **OR** ❑ No

❑ If yes, please list the medication that will be discontinued and the medication that will be initiated upon approval along with the corresponding effective date.

Medication to be discontinued: _____ **Effective date:** _____

Medication to be initiated: _____ **Effective date:** _____

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ Diagnosis: Moderate-to-Severe Rheumatoid Arthritis

Dosing: SubQ: 125 mg once weekly

- ❑ Member has a diagnosis of **moderate-to-severe rheumatoid arthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member has tried and failed at least **ONE** of the following **DMARD** therapies for at least **three (3) months**
  - ❑ hydroxychloroquine
  - ❑ leflunomide
  - ❑ methotrexate
  - ❑ sulfasalazine
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:

❑ Actemra® SC	❑ adalimumab product: Humira®, Cyltezo® or Hyrimoz®	❑ Enbrel®
❑ Rinvoq®	❑ Xeljanz®/XR®	

***NOTE:** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; Hyrimoz NDC's starting with 83457 are not approved, NDC's starting with 61314 (MFG: Sandoz) are preferred

  - ❑ Member has been established on Orencia® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Orencia was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ Diagnosis: Active Psoriatic Arthritis

Dosing: SubQ: 125 mg once weekly

- ❑ Member has a diagnosis of active **psoriatic arthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member has tried and failed at least **ONE** of the following **DMARD** therapies for at least **three (3) months**
  - ❑ cyclosporine
  - ❑ leflunomide
  - ❑ methotrexate
  - ❑ sulfasalazine

(Continued on next page)

- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:

❑ adalimumab product: Humira®, Cyltezo® or Hyrimoz®	❑ Enbrel®	❑ Otezla®	❑ Rinvoq®/ Rinvoq® LQ
	❑ Skyrizi®	❑ Stelara®	❑ Taltz®
	❑ Tremfya®	❑ Xeljanz®/XR®	

***NOTE:** Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; Hyrimoz NDC's starting with 83457 are not approved, NDC's starting with 61314 (MFG: Sandoz) are preferred

  - ❑ Member has been established on Orencia® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Orencia was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ **Diagnosis: Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis**
Dosing: SubQ: 10 to < 25 kg- 50 mg once weekly; > 25 to < 50 kg- 87.5 mg once weekly; > 50 kg- 125 mg once weekly

- ❑ Member has a diagnosis of moderate-to-severe polyarticular **juvenile idiopathic arthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member has tried and failed at least **ONE** of the following **DMARD** therapies for at least **three (3) months**
  - ❑ cyclosporine
  - ❑ hydroxychloroquine
  - ❑ leflunomide
  - ❑ methotrexate
  - ❑ Non-steroidal anti-inflammatory drugs (NSAIDs)
  - ❑ oral corticosteroids
  - ❑ sulfasalazine
  - ❑ tacrolimus

(Continued on next page)

- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the following **PREFERRED** biologics:

❑ Actemra® SC	❑ adalimumab product: Humira®, Cyltezo® or Hyrimoz®
❑ Enbrel®	❑ Rinvoq®/Rinvoq® LQ
❑ Xeljanz® tablets/oral solution	

*__NOTE:__ Humira NDC's starting with 83457 are not approved, NDC's starting with 00074 (MFG: Abbvie) are preferred; Hyrimoz NDC's starting with 83457 are not approved, NDC's starting with 61314 (MFG: Sandoz) are preferred

  - ❑ Member has been established on Orencia® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Orencia was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

Medication being provided by Specialty Pharmacy – Proprium Rx

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*

***Approved by Pharmacy and Therapeutics Committee:** ~~2/16/2006; 8/17/2023;~~ **7/26/2024**
REVISED/UPDATED/REFORMATTED: ~~10/28/2014; 5/22/2015; 12/29/2015; 3/30/3016; 5/6/2016; 6/23/2016; 8/11/2016; 9/22/2016; 12/21/2016; 8/4/2017; 12/28/2017; 1/11/2018; 12/13/2018; 11/20/2019; 5/10/2022; 6/13/2022; 6/17/2022; 12/21/2022; 8/13/2023; 3/27/2024;~~
8/21/2024